Daewoong Pharmaceutical: "Pexuclu Achieves 92% Eradication Rate for Helicobacter"

80% Eradication Success Achieved Even Among Patients with Clarithromycin Resistance-Related Mutations

On September 17, Daewoong Pharmaceutical announced that a clinical study on Helicobacter pylori eradication therapy, based on its gastroesophageal reflux disease treatment Pexuclu (active ingredient: fexuprazan hydrochloride), achieved an eradication rate of 92.0% among patients who completed the treatment.

This study was conducted in 93 patients with no previous experience of Helicobacter pylori eradication therapy. The efficacy and safety of a concomitant therapy—consisting of Pexuclu combined with three antibiotics: clarithromycin, amoxicillin, and metronidazole, administered for ten days—were evaluated. The eradication rate was 90.3% based on all enrolled patients, and 92.0% among the 88 patients who completed the treatment.

Daewoong Pharmaceutical Paxclu Tablets 40mg product image. Daewoong Pharmaceutical

In the group of patients confirmed to have clarithromycin resistance-related mutations, the eradication success rate was 80.0%. The study results were presented as a poster at the 32nd Annual Meeting of the Japanese Society for Helicobacter Research (JSHR 2026) in July, and the related paper was published online in "Digestion," the official journal of the Japanese Society of Gastroenterology, on August 26.

Helicobacter pylori eradication therapy involves the combined use of acid-suppressing agents and antibiotics. Recently, as resistance to antibiotics such as clarithromycin has been increasing, the eradication rates with conventional treatments have been declining, necessitating improved therapeutic strategies. In response, the “2025 Revised Clinical Guidelines for Evidence-Based Diagnosis and Treatment of Helicobacter pylori in Koreans” issued by the Korean College of Helicobacter and Upper Gastrointestinal Research also suggested the potential use of concomitant therapy and P-CABs as strategies to address rising antibiotic resistance.

This study also confirmed the safety of concomitant therapy using Pexuclu and three antibiotics. No severe adverse events or liver function abnormalities were observed during the research period. The research team concluded that Pexuclu-based concomitant therapy demonstrated both efficacy and tolerability as a first-line Helicobacter pylori eradication treatment.

Namhoon Kim, Professor of Gastroenterology at Ilsan Paik Hospital, stated, “This study confirmed that Pexuclu-based therapy showed a high eradication rate for first-line Helicobacter pylori treatment. In addition, eradication success was observed even among patients with clarithromycin resistance-related mutations, thereby expanding the clinical evidence that can be referenced in real-world prescriptions."

Hyungcheol Park, Head of ETC Marketing at Daewoong Pharmaceutical, said, “This study has further demonstrated the potential of Pexuclu-based combination therapy as a first-line treatment for Helicobacter pylori eradication. Going forward, we will continue to build a body of evidence that can be applied in clinical practice to broaden the therapeutic scope of Pexuclu.”

This content was produced with the assistance of AI translation services.